Genedrive (AIM:GDR), the AIM-listed point-of-care pharmacogenetic testing company, said a new UK clinical guideline has been published recommending MT-RNR1 genotype testing before aminoglycoside antibiotic treatment.
The guideline, developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics, aims to prevent antibiotic-induced hearing loss, which can follow a single dose of an aminoglycoside.
It recommends testing for people of all ages and genetic ancestries where results can be delivered within a clinically achievable timeframe.
The guideline names the Genedrive MT-RNR1 ID Kit specifically, stating point-of-care testing should be considered wherever available in acute clinical settings.
The test detects the m.1555A>G variant from a buccal swab and delivers a result in approximately 26 minutes.
"The Genedrive MT-RNR1 ID Kit is the only point-of-care MT-RNR1 test currently in routine clinical use in UK Neonatal Intensive Care Units, and these recommendations provide further support for wider NHS implementation of our test into routine acute care settings," said Dr Gino Miele, chief executive of Genedrive.
The guidance also references the National Institute for Health and Care Excellence's Early Value Assessment, which recommends the kit for newborns while further evidence is gathered.
NICE's early economic modelling suggested the test could be cost-saving and more effective than standard care.
NICE has said evidence from the PALOH-UK programme will feed into its planned review of that guidance.
News Intelligence what this means for the company
The UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics has published a clinical guideline recommending MT-RNR1 genotype testing before aminoglycoside treatment, with explicit naming of Genedrive's point-of-care kit for use in acute care settings. This endorsement follows earlier deployment in NHS neonatal intensive care units and NICE's Early Value Assessment backing, and directly addresses the regulatory and clinical validation pathway needed to drive wider NHS adoption beyond the current neonatal footprint.
The guideline recommendation materially strengthens Genedrive's case for routine acute care adoption across the NHS, removing a key clinical validation barrier. However, the company remains dependent on converting this endorsement into actual procurement and reimbursement decisions, and faces a funding inflection as PALOH-UK grant funding concluded in June 2026.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
